We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.29%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.31B
AUM Growth
+$931M
Cap. Flow
+$3.42M
Cap. Flow %
0.05%
Top 10 Hldgs %
41.19%
Holding
233
New
22
Increased
88
Reduced
44
Closed
17

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$66M
2
CRL icon
Charles River Laboratories
CRL
+$38M
3
WVE icon
Wave Life Sciences
WVE
+$20.8M
4
ABT icon
Abbott
ABT
+$19M
5
PACB icon
Pacific Biosciences
PACB
+$17.1M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$108M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$84.7M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$53.2M
4
GILD icon
Gilead Sciences
GILD
+$35.4M
5
TDOC icon
Teladoc Health
TDOC
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.59%
2 Industrials 0.45%
3 Technology 0.42%
4 Communication Services 0.09%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WAB icon
176
Wabtec
WAB
$51.1B
$498K 0.01%
6,400
– –
ADBE icon
177
Adobe
ADBE
$89.5B
$495K 0.01%
1,500
– –
TRMB icon
178
Trimble
TRMB
$12.3B
$488K 0.01%
11,700
– –
ADI icon
179
Analog Devices
ADI
$181B
$487K 0.01%
4,100
– –
SQM icon
180
Sociedad Química y Minera de Chile
SQM
$19.6B
$486K 0.01%
18,200
– –
MCO icon
181
Moody's
MCO
$82.4B
$475K 0.01%
2,000
– –
MKC icon
182
McCormick & Company Non-Voting
MKC
$13.4B
$475K 0.01%
5,600
– –
POOL icon
183
Pool Corp
POOL
$6.7B
$467K 0.01%
2,200
– –
RVTY icon
184
Revvity
RVTY
$12.3B
$466K 0.01%
+4,800
New +$428K
ANSS
185
DELISTED
Ansys
ANSS
$464K 0.01%
1,802
– –
EL icon
186
Estee Lauder
EL
$29B
$464K 0.01%
2,248
– –
SPGI icon
187
S&P Global
SPGI
$126B
$464K 0.01%
1,700
– –
MSCI icon
188
MSCI
MSCI
$40B
$461K 0.01%
1,786
– –
PAYX icon
189
Paychex
PAYX
$40.4B
$459K 0.01%
5,400
– –
TYL icon
190
Tyler Technologies
TYL
$12.2B
$458K 0.01%
1,525
– –
MKL icon
191
Markel Group
MKL
$25B
$457K 0.01%
400
– –
FDS icon
192
Factset
FDS
$9.05B
$456K 0.01%
+1,700
New +$437K
CERN
193
DELISTED
Cerner Corp
CERN
$455K 0.01%
6,200
– –
AXP icon
194
American Express
AXP
$223B
$448K 0.01%
3,600
– –
ICE icon
195
Intercontinental Exchange
ICE
$82.4B
$444K 0.01%
4,800
– –
LYV icon
196
Live Nation Entertainment
LYV
$41.2B
$443K 0.01%
6,200
– –
TCOM icon
197
Trip.com Group
TCOM
$27.5B
$439K 0.01%
13,100
– –
IBKR icon
198
Interactive Brokers
IBKR
$40.9B
$438K 0.01%
37,600
– –
TRU icon
199
TransUnion
TRU
$14.8B
$436K 0.01%
+5,096
New +$424K
CLX icon
200
Clorox
CLX
$11.6B
$430K 0.01%
2,800
– –
6 7
8
9 10

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2019 Portfolio in Review

As of Q4 2019, Bellevue Group held 233 positions worth $6.31B, up 17% from $5.38B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q4 2019 filing shows 22 new, 88 increased, 44 reduced and 17 closed positions. Its largest new stake was Molecular Templates, Inc.: 86,379 shares worth $18.1M. The largest sale was Celgene Corp, an estimated $108M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q4 2019 buy was Molecular Templates, Inc.: 86,379 shares worth $18.1M.
  • Bellevue Group added most to Bristol-Myers Squibb in Q4 2019, an estimated $66M increase.
  • Bellevue Group's biggest Q4 2019 reduction was Audentes Therapeutics, Inc, cutting an estimated $53.2M.
  • Bellevue Group fully exited Celgene Corp in Q4 2019, selling an estimated $108M.
  • Bellevue Group's ten largest holdings make up 41% of its $6.31B portfolio in Q4 2019.
  • Bellevue Group opened 22 new positions and closed 17 in Q4 2019.
  • Bellevue Group's portfolio value rose 17% quarter-over-quarter to $6.31B.

Based on Bellevue Group's 13F filing for Q4 2019, filed 14 Feb 2020.